Edge Therapeutics, Inc. (EDGE) Forms $10.77 Double Top; Tax Exempt Securities Trust Series 289 (CBM)’s Sentiment Is 1.58

Edge Therapeutics, Inc. (EDGE) formed double top with $11.09 target or 3.00% above today’s $10.77 share price. Edge Therapeutics, Inc. (EDGE) has $332.35 million valuation. The stock decreased 3.32% or $0.37 during the last trading session, reaching $10.77. About 209,953 shares traded or 189.18% up from the average. Edge Therapeutics, Inc. (NASDAQ:EDGE) has risen 23.72% since January 16, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.69 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 17.3 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Analysts await Edge Therapeutics, Inc. (NASDAQ:EDGE) to report earnings on March, 1. They expect $-0.47 EPS, down 42.42% or $0.14 from last year’s $-0.33 per share. After $-0.37 actual EPS reported by Edge Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 27.03% negative EPS growth.

Among 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Edge Therapeutics has $34 highest and $18 lowest target. $27.25’s average target is 153.02% above currents $10.77 stock price. Edge Therapeutics had 5 analyst reports since October 26, 2015 according to SRatingsIntel. JMP Securities initiated Edge Therapeutics, Inc. (NASDAQ:EDGE) rating on Monday, October 26. JMP Securities has “Market Outperform” rating and $34 target. The rating was initiated by Guggenheim with “Buy” on Monday, October 26. On Monday, October 26 the stock rating was initiated by Leerink Swann with “Outperform”. The firm has “Outperform” rating by Credit Suisse given on Monday, October 26. The company was maintained on Monday, May 9 by Credit Suisse.

The stock decreased 0.29% or $0.15 during the last trading session, reaching $51.65. About 151,200 shares traded. Cambrex Corporation (CBM) has risen 11.15% since January 16, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Ranger Investment Management L.P. holds 2.91% of its portfolio in Cambrex Corporation for 704,978 shares. Zpr Investment Management owns 34,205 shares or 2.85% of their US portfolio. Moreover, Jw Asset Management Llc has 2.04% invested in the company for 50,519 shares. The New York-based American Capital Management Inc has invested 1.94% in the stock. Neumeier Poma Investment Counsel Llc, a California-based fund reported 335,675 shares.

Analysts await Cambrex Corporation (NYSE:CBM) to report earnings on February, 2. They expect $1.11 EPS, down 5.93% or $0.07 from last year’s $1.18 per share. CBM’s profit will be $36.38M for 11.63 P/E if the $1.11 EPS becomes a reality. After $0.55 actual EPS reported by Cambrex Corporation for the previous quarter, Wall Street now forecasts 101.82% EPS growth.

Since January 1, 0001, it had 0 insider buys, and 3 insider sales for $1.57 million activity.